Outcome of patients with diffuse large b-cell lymphoma relapsing after autologous transplant before availability of car-t cell treatment

Conclusions:Additional therapies can extend OS, but mostly cannot prevent death in DLBCL relapsing/refractory post-ASCT. This study may serve as reference to emerging results after CAR-T treatment in this population.

Source: Mediterranean Journal of Hematology and Infectious Diseases - April 28, 2023 Category: Hematology Authors: Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst Source Type: research